American Association for the Advancement of Science, Science Immunology, 38(4), 2019
DOI: 10.1126/sciimmunol.aav6473
Full text: Unavailable
Proper dosing and timing of EGFR TKI can trigger antitumor T cell responses and potentiate anti–PD-L1 immunotherapy.